Macroeconomic headwinds, compressed regulatory pathways, and an influx of asset-light virtual innovators are leading to an evolution in outsourcing service delivery models.

A novel pan-sarbecovirus vaccine candidate developed by the University of Cambridge and DIOSynVax has demonstrated safety in a Phase I, needle-free clinical trial.

SPONSORED CONTENT: Pedro Fernandes Botas and Mark Macdonald from Codis break down how advanced spray drying capabilities, mathematical modeling, and commercial operations experience are helping sponsors navigate the modern formulation landscape.

As specialized modalities push classical manufacturing models to their limits, organizations must treat internal talent development with the same level of process excellence they apply to biological pipelines.

Industry leaders are set to gather in Philadelphia to address fluctuating policy shifts, supply chain risks, and accelerating biologics investment across the global industry.

As bio/pharmaceutical drug development progresses and more complex molecules enter the pipeline, increased innovation and a rethink of excipient portfolios is necessary.

Marking Clinical Trial Awareness Day, Treehill Partners’ CEO Ali Pashazadeh details the flaws in clinical study designs and explains how high-velocity competition from Eastern markets is forcing a long-overdue industry redesign.

SPONSORED CONTENT: Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a need for simpler platform approaches, according to Kenneth Holbourn from FUJIFILM Biotechnologies.

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.

Driven by regulatory evolution and a commitment to sustainability, the excipients’ sector is reinforcing its position as a sophisticated and credible stakeholder in the modern pharmaceutical supply chain.

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Patient outcomes are transforming, thanks to innovative, curative, tailored therapies; however, industry needs to address a few pressing issues to ensure the huge promise of these drugs can be achieved.

While advancements are unlocking new possibilities in inhaled drug delivery and the pipeline is strong, the regulatory landscape is still challenging, highlighting the need for specialized partners to unlock future success.

Traditional antibody discovery is notoriously slow and resource-intensive, but a new wave of AI tools is enabling optimization of candidates prior to them reaching the clinic, accelerating development timelines. 

Despite geopolitical uncertainties, regulatory reforms, and fluctuating capital expenditure, the bio/pharma industry is entering 2026 with renewed focus and confidence.

Facing a world of political risk and scientific hurdles, pharma companies are downsizing internal footprints to focus on portfolio management while leaning on CDMOs for specialized execution, explains Owen Murray from Bend Bioscience.

From managing high viscosity to preventing agglomeration, the industry is shifting toward larger-volume, device-compatible solutions that prioritize both drug stability and healthcare efficiency, points out Dr. Robert Lindner from SCHOTT Pharma.

Changes to sustainability reporting requirements are leading to renewed focus on supplier tools and packaging tenders, and driving a greater need for industry to adapt to ESG standards, reveals Morten Munk from FUJIFILM Biotechnologies.

To efficiently and accurately target the immune-rich dermal layer, drug delivery devices must overcome user-dependent variables, explains Michele Guasti from Terumo Medical Care Solutions.

According to Christian Classen from Sanner Group, packaging decisions made too late in the development cycle often lead to avoidable failures in scalability and supply continuity.